US · Healthcare · Drug Manufacturers - General
EPS came in at 3.65 against a street estimate of 3.64 — a beat of 0.3%.
Analysts rate AbbVie Inc a buy (24 buy, 5 hold, 1 sell out of 30) with an average price target of $282.61.
CONFIDENT AbbVie crushed Q2 with 10.2% revenue growth, beating guidance by $300M. Skyrizi and Rinvoq surging 24% and 24% respectively. Full-year revenue raised $600M total. Pipeline advancing with multiple approvals; Apogee acquisition bolsters immunology. Q2 2026 Geographic performance not separately disclosed in call. Analysts pressed on Skyrizi defensibility vs. newer agents, immunology combination strategies, and oncology ADC differentiation. Management emphasized market expansion over displacement, strong efficacy/safety data, and biomarker-directed strategies as defensibility moats. 2026-07-31…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.46% |
| Vanguard Capital Management, LLC | 6.53% |
| State Street Corp | 4.67% |
| Vanguard Portfolio Management, LLC | 2.74% |
| JPMorgan Chase & Co | 2.71% |
| Geode Capital Management, LLC | 2.66% |
| Morgan Stanley - Brokerage Accounts | 2.20% |
| Capital Research Global Investors | 1.70% |
| Document | Date |
|---|---|
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • AbbVie filed a Form 8-K dated October 14, 2026, reporting a change to its Board of Directors. • The Board expanded from twelv | 2026-10-15 |
| Results announced · Q4 2026 HEADLINE NUMBERS • AbbVie expects third-quarter 2026 results to include $216 million of pre-tax acquired in-process research and development (IPR&D) | 2026-10-05 |
| Reg FD disclosure · Q3 2026 ABBVIE INC. - FORM 8-K SUMMARY (SEPTEMBER 3, 2026) HEADLINE NUMBERS • AbbVie completed acquisition of Apogee Therapeutics, Inc. on September 3, 2026 | 2026-09-03 |
| Company announcement · Q3 2026 ABBVIE INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • AbbVie completed an underwritten public offering of $9,000,000,000 in senior notes across nine dif | 2026-08-18 |
| Company announcement · Q3 2026 ABBVIE INC. - FORM 8-K SUMMARY (August 4, 2026) HEADLINE NUMBERS • Total debt issuance: $9.5 billion in senior notes across multiple maturity dates | 2026-08-05 |
| Quarterly report · Q2 2026 ABBVIE INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Revenues (Q2 2026): $16,990 million vs. $15,423 million (Q2 2025) — up 10.1% • Net Revenue | 2026-08-03 |
| Results announced · Q3 2026 ABBVIE Q2 2026 FINANCIAL RESULTS – INVESTOR SUMMARY HEADLINE NUMBERS • Q2 2026 Total Net Revenues: $16.990 billion — up 10.2% reported basis, 9.5% o | 2026-07-31 |
| Quarterly report · Q1 2026 ABBVIE INC. - Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Net revenues Q1 2026: $15,002 million vs. $13,343 million Q1 2025 (+12.4%) • Net earnings | 2026-05-08 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $1.73 / share ex-date Oct 15, 2026 · pay Nov 16, 2026 | 2026-10-15 |
| Dividend | $1.73 / share ex-date Jul 15, 2026 · pay Aug 14, 2026 | 2026-07-15 |
| Dividend | $1.73 / share ex-date Apr 15, 2026 · pay May 15, 2026 | 2026-04-15 |
| Dividend | $1.73 / share ex-date Jan 16, 2026 · pay Feb 17, 2026 | 2026-01-16 |
| Dividend | $1.64 / share ex-date Oct 15, 2025 · pay Nov 14, 2025 | 2025-10-15 |
| Announcement | Date |
|---|---|
| Updated 2026 adjusted EPS guidance to include third-quarter acquired IPR and milestones expense AbbVie said its preliminary third-quarter 2026 results will include $216 million of pre-tax acquired in-process research and development (IPR&D) and milestone expenses. These charges are tie | 2026-10-05 |
| Completion of acquisition of Apogee Therapeutics AbbVie Inc. completed its acquisition of Apogee Therapeutics on September 3, 2026. Apogee brings two key pipeline assets: zumilokibart (APG777) and APG273, which are expected to strengthen A | 2026-09-03 |
| Full-year 2026 adjusted diluted earnings per share guidance range updated AbbVie announced that Q2 2026 earnings will include a $291 million pre-tax expense related to acquired in-process research and development (IPR&D) and milestone payments. This one-time charg | 2026-07-06 |
| Definitive agreement to acquire Apogee Therapeutics announced AbbVie Inc. announced on June 22, 2026, that it has agreed to acquire Apogee Therapeutics, Inc. in a definitive merger agreement. This is a strategic acquisition in the pharmaceutical sector | 2026-06-22 |
| Full-year 2026 adjusted EPS guidance updated to $13.96-$14.16 AbbVie announced a $744 million pre-tax charge in Q1 2026 for acquired in-process research and development (IPR&D) and milestone expenses related to licensing agreements and asset acquisitio | 2026-04-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AbbVie Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.